Alan E Moormann
Research Subjects
Research Interests
Alan E Moormann has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
A J Wittwer
1 shared publicationA Rankin
1 shared publicationB C Holwerda
1 shared publicationBarnett S Pitzele
1 shared publicationC I Villamil
1 shared publicationChristine Kornmeier
1 shared publication
Latest Publications
- 1 October 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (19) , 2651-2653
Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase
- 1 October 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (19) , 2651-2653
Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase
- 1 May 1997
- Vol. 15 (1) , 3-15
The herpesvirus protease: mechanistic studies and discovery of inhibitors of the human cytomegalovirus protease.
The herpesvirus protease is a recently identified enzyme which is essential for viral replication. It is found in all herpesviruses and offers a new molecular target for therapeutic intervention. Its genomic structure has recently been described and consists of a large open reading frame which encodes a fusion protein containing an amino-terminal protease domain in-frame with a carboxyl-terminal "assembly protein-like" domain. Auto-processing releases the amino-terminal protease as a maturational enzyme. The herpesvirus protease has been characterized as a novel serine protease. Four surface accessible sulfhydryl groups have been identified in the human cytomegalovirus (HCMV) protease. Utilizing a fluorogenic DABCYL-EDANS substrate assay, directed screening has identified a class of sulfhydryl-modifying benzimidazolylmethyl sulfoxides which inhibits recombinant HCMV protease. Site-directed mutagenesis studies suggest oxidative modification of surface-accessible HCMV protease Cys138 (and possibly Cys161) by this class of inhibitors. The benzimidazolylmethyl sulfoxide 1 inhibits HCMV protease (IC50 = 1.9 microM), exhibits selectivity vs. mammalian serine proteases, and exhibits antiviral activity in an HCMV infected cell culture assay.
- 1 May 1997
- Vol. 15 (1) , 3-15
The herpesvirus protease: mechanistic studies and discovery of inhibitors of the human cytomegalovirus protease.
The herpesvirus protease is a recently identified enzyme which is essential for viral replication. It is found in all herpesviruses and offers a new molecular target for therapeutic intervention. Its genomic structure has recently been described and consists of a large open reading frame which encodes a fusion protein containing an amino-terminal protease domain in-frame with a carboxyl-terminal "assembly protein-like" domain. Auto-processing releases the amino-terminal protease as a maturational enzyme. The herpesvirus protease has been characterized as a novel serine protease. Four surface accessible sulfhydryl groups have been identified in the human cytomegalovirus (HCMV) protease. Utilizing a fluorogenic DABCYL-EDANS substrate assay, directed screening has identified a class of sulfhydryl-modifying benzimidazolylmethyl sulfoxides which inhibits recombinant HCMV protease. Site-directed mutagenesis studies suggest oxidative modification of surface-accessible HCMV protease Cys138 (and possibly Cys161) by this class of inhibitors. The benzimidazolylmethyl sulfoxide 1 inhibits HCMV protease (IC50 = 1.9 microM), exhibits selectivity vs. mammalian serine proteases, and exhibits antiviral activity in an HCMV infected cell culture assay.